# Multiple Myeloma Research and Treatments

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/multiple-myeloma-research-and-treatments/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the diagnosis, staging, treatment, and molecular classification of multiple myeloma. It covers topics such as the International Myeloma Working Group criteria, novel therapies including proteasome inhibitors and immunomodulatory drugs, autologous transplantation, genomic abnormalities, and the role of the bone marrow microenvironment in disease progression. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10649 |
| Works | 198 |

## Topic papers all

Showing 15 of 198.

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Antitumor Activity of Thalidomide in Refractory Multiple Myeloma](https://scholariq.org/papers/antitumor-activity-of-thalidomide-in-refractory-multiple-myeloma/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells](https://scholariq.org/papers/lenalidomide-causes-selective-degradation-of-ikzf1-and-ikzf3-in-multiple-myeloma/)
- [Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/anti-bcma-car-t-cell-therapy-bb2121-in-relapsed-or-refractory-multiple-myeloma/)
- [Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study](https://scholariq.org/papers/ciltacabtagene-autoleucel-a-b-cell-maturation-antigen-directed-chimeric-antigen/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4](https://scholariq.org/papers/hijacking-the-e3-ubiquitin-ligase-cereblon-to-efficiently-target-brd4/)
- [Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist](https://scholariq.org/papers/rapid-mobilization-of-murine-and-human-hematopoietic-stem-and-progenitor-cells/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-combination-therapy-in-patients-with/)
- [PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer](https://scholariq.org/papers/protac-induced-bet-protein-degradation-as-a-therapy-for-castration-resistant/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma](https://scholariq.org/papers/immunomodulatory-drug-cc-5013-overcomes-drug-resistance-and-is-well-tolerated-in/)

## Topic primary papers

Showing 15 of 106.

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Antitumor Activity of Thalidomide in Refractory Multiple Myeloma](https://scholariq.org/papers/antitumor-activity-of-thalidomide-in-refractory-multiple-myeloma/)
- [Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells](https://scholariq.org/papers/lenalidomide-causes-selective-degradation-of-ikzf1-and-ikzf3-in-multiple-myeloma/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-combination-therapy-in-patients-with/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma](https://scholariq.org/papers/immunomodulatory-drug-cc-5013-overcomes-drug-resistance-and-is-well-tolerated-in/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6](https://scholariq.org/papers/paracrine-rather-than-autocrine-regulation-of-myeloma-cell-growth-and/)
- [Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma](https://scholariq.org/papers/thalidomide-and-hematopoietic-cell-transplantation-for-multiple-myeloma/)
- [Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial](https://scholariq.org/papers/daratumumab-lenalidomide-bortezomib-and-dexamethasone-for-transplant-eligible/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma](https://scholariq.org/papers/talquetamab-a-t-cell-redirecting-gprc5d-bispecific-antibody-for-multiple-myeloma/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.